Compares proton and photon extended-field radiation for cervical cancer
Compares proton and photon extended-field radiation in people with cervical cancer.
Plain-language title generated from the registry record
Registry title: Extended-field Proton Therapy for Cervical Cancer
Key facts
- Where
- Taipei and Taoyuan, TaiwanSee the 2 sites
- Phase
- Phase 2/3
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 20 and 85 years old?
Source: NCT07298642, who can take part
Where in Taiwan
- National Taiwan University HospitalTaipei, TaiwanTaking people
- Chang Gung Memorial HospitalTaoyuan, TaiwanTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- National Taiwan University Hospital
- Trial code
- NCT07298642
- Record updated
- 23 December 2025
- Original description
Severe lymphopenia is a common complication of extended-field radiotherapy in cervical cancer, significantly impacting immune function and clinical outcomes. This study aims to evaluate whether proton therapy, with its superior dose distribution, can reduce lymphopenia and improve survival and toxicity profiles compared to photon therapy.Read full original descriptionShow less
Proton Therapy in Extended-field Irradiation for Cervical Cancer
Severe lymphopenia is a common complication of extended-field radiotherapy in cervical cancer, significantly impacting immune function and clinical outcomes. This study aims to evaluate whether proton therapy, with its superior dose distribution, can reduce lymphopenia and improve survival and toxicity profiles compared to photon therapy.
Inclusion: Histologically confirmed cervical cancer, stage ≥ IIIC; Age between 20 and 85 years; Eastern Cooperative Oncology Group (ECOG) performance status of 0-1; Eligible for extended-field radiotherapy as determined by the treating physician; Induction chemotherapy with paclitaxel and carboplatin is allowed if the duration is ≤ 6 weeks or ≤ 2 cycles; RT alone, or concurrent single-agent chemotherapy with weekly cisplatin or carboplatin during radiation therapy is allowed, while the use of any other concurrent antineoplastic agents is prohibited; Consolidative chemotherapy or immunotherapy after radiation therapy is allowed.
Exclusion: Prior history of pelvic or abdominal radiotherapy; Presence of distant metastases or other active malignancies within the past 5 years, excluding non-melanoma skin cancer; Severe comorbid conditions, such as uncontrolled diabetes, cardiovascular disease, or autoimmune disorders, that may interfere with treatment or study participation; Psychiatric or social conditions that would limit compliance with study requirements or follow-up; Pregnancy or breastfeeding at the time of enrollment.